Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India.
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Indian Heart J. 2021 Jan-Feb;73(1):135-137. doi: 10.1016/j.ihj.2020.12.013. Epub 2020 Dec 30.
of the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by Percutaneous Coronary Intervention (ATPCI) study showed no significant difference in the incidence of primary endpoint events between trimetazidine and placebo group in angina patients who recently underwent percutaneous coronary intervention. However, the study had limitations specific to both, design and selection of patient population. Here, we present some explanations for the null effects of trimetazidine in the ATPCI study and their relevance in routine clinical practice.
关于曲美他嗪在经皮冠状动脉介入治疗(ATPCI)后心绞痛患者中的疗效和安全性的研究表明,在近期接受经皮冠状动脉介入治疗的心绞痛患者中,曲美他嗪组与安慰剂组的主要终点事件发生率无显著差异。然而,该研究存在设计和患者人群选择方面的局限性。在这里,我们对 ATPCI 研究中曲美他嗪无效的原因及其在常规临床实践中的相关性进行了一些解释。